Crucell, DSM Biologics Announce PER.C6 Agreement With MorphoSys

March 17, 2008
Dutch biotechnology company Crucell N.V. and DSM Biologics, a business unit of DSM Pharmaceutical Products, announced that German-based MorphoSys AG has decided to extend the PER.C6 technology licensing agreement entered in September 2004, exercising an option for clinical and commercial production of antibodies.
The Earth Times